These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

260 related articles for article (PubMed ID: 21389097)

  • 21. Divergent effects of 4-1BB antibodies on antitumor immunity and on tumor-reactive T-cell generation.
    Kim JA; Averbook BJ; Chambers K; Rothchild K; Kjaergaard J; Papay R; Shu S
    Cancer Res; 2001 Mar; 61(5):2031-7. PubMed ID: 11280763
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effective priming of cytotoxic T lymphocyte precursors by subcutaneous administration of peptide antigens in liposomes accompanied by anti-CD40 and anti-CTLA-4 antibodies.
    Ito D; Ogasawara K; Matsushita K; Morohashi T; Namba K; Matsuki N; Kitaichi N; Inuyama Y; Hosokawa M; Nakayama E; Iwabuchi K; Onoé K
    Immunobiology; 2000 Apr; 201(5):527-40. PubMed ID: 10834311
    [TBL] [Abstract][Full Text] [Related]  

  • 23. CD40 monoclonal antibody activation of antigen-presenting cells improves therapeutic efficacy of tumor-specific T cells.
    Bergstrom RT; Silverman DA; Chambers K; Kim JA
    Otolaryngol Head Neck Surg; 2004 Jan; 130(1):94-103. PubMed ID: 14726917
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Antitumor effects of systemic and local immunization with a CTL-directed peptide in combination with a local injection of OK-432.
    Ono T; Harada M; Yamada A; Tanaka M; Takao Y; Tanaka Y; Mine T; Sakamoto K; Nakashima T; Itoh K
    Clin Cancer Res; 2006 Feb; 12(4):1325-32. PubMed ID: 16489090
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Split peripheral tolerance: CD40 ligation blocks tolerance induction for CD8 T cells but not for CD4 T cells in response to intestinal antigens.
    Chung Y; Ko SY; Ko HJ; Kang CY
    Eur J Immunol; 2005 May; 35(5):1381-90. PubMed ID: 15827964
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Activation of dendritic cells that cross-present tumor-derived antigen licenses CD8+ CTL to cause tumor eradication.
    van Mierlo GJ; Boonman ZF; Dumortier HM; den Boer AT; Fransen MF; Nouta J; van der Voort EI; Offringa R; Toes RE; Melief CJ
    J Immunol; 2004 Dec; 173(11):6753-9. PubMed ID: 15557168
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Anti-metastatic effect of vascular endothelial growth factor receptor 2 extracellular domain gene-modified dendritic cell vaccination in murine model with experimental pulmonary metastasis].
    Pan JP; Weng YS; Wu QQ
    Zhonghua Zhong Liu Za Zhi; 2006 Sep; 28(9):646-9. PubMed ID: 17274366
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Synergistic augmentation of CD40-mediated activation of antigen-presenting cells by amphiphilic poly(γ-glutamic acid) nanoparticles.
    Broos S; Sandin LC; Apel J; Tötterman TH; Akagi T; Akashi M; Borrebaeck CA; Ellmark P; Lindstedt M
    Biomaterials; 2012 Sep; 33(26):6230-9. PubMed ID: 22687756
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The boosting effect of co-transduction with cytokine genes on cancer vaccine therapy using genetically modified dendritic cells expressing tumor-associated antigen.
    Ojima T; Iwahashi M; Nakamura M; Matsuda K; Naka T; Nakamori M; Ueda K; Ishida K; Yamaue H
    Int J Oncol; 2006 Apr; 28(4):947-53. PubMed ID: 16525645
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Deliberately provoking local inflammation drives tumors to become their own protective vaccine site.
    Jackaman C; Lew AM; Zhan Y; Allan JE; Koloska B; Graham PT; Robinson BW; Nelson DJ
    Int Immunol; 2008 Nov; 20(11):1467-79. PubMed ID: 18824504
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Induction of potent and long-lasting CD4 and CD8 T-cell responses against hepatitis C virus by immunization with viral antigens plus poly(I:C) and anti-CD40.
    Zabaleta A; Arribillaga L; Llopiz D; Dotor J; Lasarte JJ; Prieto J; Borrás-Cuesta F; Esteban JI; Quer J; Vayreda F; Sarobe P
    Antiviral Res; 2007 Apr; 74(1):25-35. PubMed ID: 17275104
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Two distinct mechanisms of augmented antitumor activity by modulation of immunostimulatory/inhibitory signals.
    Mitsui J; Nishikawa H; Muraoka D; Wang L; Noguchi T; Sato E; Kondo S; Allison JP; Sakaguchi S; Old LJ; Kato T; Shiku H
    Clin Cancer Res; 2010 May; 16(10):2781-91. PubMed ID: 20460483
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Optimising anti-tumour CD8 T-cell responses using combinations of immunomodulatory antibodies.
    Gray JC; French RR; James S; Al-Shamkhani A; Johnson PW; Glennie MJ
    Eur J Immunol; 2008 Sep; 38(9):2499-511. PubMed ID: 18792403
    [TBL] [Abstract][Full Text] [Related]  

  • 34. IL-2/CD40-driven NK cells install and maintain potency in the anti-mesothelioma effector/memory phase.
    Jackaman C; Lansley S; Allan JE; Robinson BW; Nelson DJ
    Int Immunol; 2012 Jun; 24(6):357-68. PubMed ID: 22354912
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Autogeneic rna-electroporated CD40-ligand activated b-cells from hepatocellular carcinoma patients induce CD8+ T-cell responses ex vivo.
    Shen S; Xu Z; Qian X; Ding Y; Yu L; Liu B
    Exp Oncol; 2007 Jun; 29(2):137-43. PubMed ID: 17704747
    [TBL] [Abstract][Full Text] [Related]  

  • 36. CD40 activation boosts T cell immunity in vivo by enhancing T cell clonal expansion and delaying peripheral T cell deletion.
    Maxwell JR; Campbell JD; Kim CH; Vella AT
    J Immunol; 1999 Feb; 162(4):2024-34. PubMed ID: 9973474
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Dendritic cell activation by combined exposure to anti-CD40 plus interleukin (IL)-12 and IL-18 efficiently stimulates anti-tumor immunity.
    Balkow S; Loser K; Krummen M; Higuchi T; Rothoeft T; Apelt J; Tuettenberg A; Weishaupt C; Beissert S; Grabbe S
    Exp Dermatol; 2009 Jan; 18(1):78-87. PubMed ID: 19054060
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Anti-4-1BB monoclonal antibody enhances rejection of large tumor burden by promoting survival but not clonal expansion of tumor-specific CD8+ T cells.
    May KF; Chen L; Zheng P; Liu Y
    Cancer Res; 2002 Jun; 62(12):3459-65. PubMed ID: 12067989
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Central role of tumor-associated CD8+ T effector/memory cells in restoring systemic antitumor immunity.
    Kilinc MO; Gu T; Harden JL; Virtuoso LP; Egilmez NK
    J Immunol; 2009 Apr; 182(7):4217-25. PubMed ID: 19299720
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Anti-ICAM-2 monoclonal antibody synergizes with intratumor gene transfer of interleukin-12 inhibiting activation-induced T-cell death.
    Melero I; Gabari I; Tirapu I; Arina A; Mazzolini G; Baixeras E; Feijoo E; Alfaro C; Qian C; Prieto J
    Clin Cancer Res; 2003 Sep; 9(10 Pt 1):3546-54. PubMed ID: 14506140
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.